Resona Asset Management Co. Ltd. Sells 7,205 Shares of DexCom, Inc. $DXCM

Resona Asset Management Co. Ltd. lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.6% in the fourth quarter, Holdings Channel reports. The firm owned 122,583 shares of the medical device company’s stock after selling 7,205 shares during the period. Resona Asset Management Co. Ltd.’s holdings in DexCom were worth $8,162,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. CVA Family Office LLC boosted its position in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. ORG Partners LLC boosted its position in DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the period. Spire Wealth Management boosted its position in DexCom by 113.8% during the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after purchasing an additional 305 shares during the period. Aventura Private Wealth LLC bought a new stake in DexCom during the fourth quarter worth approximately $43,000. Finally, Rothschild Investment LLC boosted its position in DexCom by 59.9% during the third quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock worth $44,000 after purchasing an additional 245 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $71.90 on Friday. The business has a fifty day simple moving average of $63.46 and a 200 day simple moving average of $65.94. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $27.74 billion, a price-to-earnings ratio of 30.73, a PEG ratio of 1.18 and a beta of 1.40. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.32 earnings per share. Sell-side analysts expect that DexCom, Inc. will post 2.57 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,112 shares of company stock valued at $379,990 over the last quarter. Corporate insiders own 0.28% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on DXCM shares. TD Cowen reduced their price objective on DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Robert W. Baird set a $80.00 price objective on DexCom in a research report on Friday, May 1st. Truist Financial restated a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Benchmark assumed coverage on DexCom in a research note on Monday, May 11th. They issued a “buy” rating and a $77.00 target price for the company. Finally, Piper Sandler restated an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $82.21.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.